Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > REGULATORY
REGULATORY
- Komeito’s Exit from Ruling Coalition Casts Uncertainty over Japan’s Drug Policy
October 15, 2025
- Japan to Continue Subsidies for Domestic Biosimilar Production: MHLW Official
October 15, 2025
- MHLW to Clarify Criteria for Japanese PI Waivers through Q&A, Calls for Data-Based Justifications
October 14, 2025
- Japan’s Healthcare Spending Reaches 48.1 Trillion Yen in FY2023
October 14, 2025
- PMDA Lays Out AI Action Plan, Eyes Specialized In-House System
October 14, 2025
- MHLW Panel OKs 19th Edition of Japanese Pharmacopoeia; 27 New Products Added
October 14, 2025
- MHLW Maps Out Action Plan to Tackle Drug Supply Disruptions
October 14, 2025
- Eto to Stay as LDP Pharma Study Group Chair Even After Exiting Politics
October 10, 2025
- GS1 Barcode Adoption Stalls at 40% of Hospitals, Pharmacist Urges Subsidies
October 10, 2025
- MHLW to Disclose Review Reports for Conditionally Cleared Regenerative Therapies Even If Full Approval Bid Dropped
October 10, 2025
- Japan Launches Study on Legal Framework for Patent Linkage System
October 9, 2025
- Chuikyo Frowns on Industry Calls for Scrapping Huge-Seller Re-Pricing, Spillovers
October 9, 2025
- Chuikyo Wary of Revising “Zero” Premium Rule for Low Cost Disclosure
October 9, 2025
- Komeito Calls for Careful Study of Re-Pricing Rules for CAR-T Therapies
October 9, 2025
- Elevidys Coverage Debate to Resume after MHLW Gains Broad Understanding on Safety
October 9, 2025
- Japan Begins Overhaul of Patent Linkage Framework with First Notification
October 8, 2025
- Japan Panel OKs Basic Policy for Stockpiling Crisis-Response Medicines
October 8, 2025
- Turn Sakaguchi’s Nobel-Winning Research into Societal Impact: LDP Panel Chief
October 8, 2025
- Takaichi Vows Hospital Support via Extra Budget; MHLW Sees Boost for Funding Requests
October 7, 2025
- Japan to Allow Vaccine Strain Changes Under PACMP Framework
October 6, 2025
ページ
Japan’s FY2026 drug pricing reform will, for the first time, apply the “G1” price cut rule for long-listed original biologics…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…